Ovarian Cancer Clinical Trials

Showing 661-680 of 902 trials

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

NCT00003532

Current therapies for Stage III or IV Ovarian Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage III or IV Ovarian Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage III or IV Ovarian Cancer.

Stage III Ovarian CancerStage IV Ovarian Cancer

Burzynski Research Institute7 participantsStarted Mar 1996

Houston, Texas, United States

TERMINATEDPhase 3

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

NCT01281254

To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS) The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo plus PLD in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer

Amgen223 participantsStarted Apr 2011

Los Angeles, California, United States • San Francisco, California, United States • Norwalk, Connecticut, United States +103 more locations

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Related Searches

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.

Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients

Pillars4Life Trial

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

Ovarian Cancer Vaccine for Patients in Remission

Blood Samples From Patients on a Clinical Trial to CINV During HSCT